Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of orelabrutinib + rituximab + methotrexate in untreated primary central nervous system lymphoma
ChiCTR2100049862Phase 2Not yet recruiting
- Sponsor
- Department of Lymphoma and Plasmacytoma, Senior Department of Hematology, Chinese PLA General Hospital
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib, rituximab and methotrexate in primary central nervous system lymphoma (PCNSL), sponsored by Department of Lymphoma and Plasmacytoma, Senior Department of Hematology, Chinese PLA General Hospital. Primary endpoints: Overall response rate and Complete response rate. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
orelabrutinibrituximabmethotrexate
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on ChiCTR2100049862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049862.